| Name | Title | Contact Details |
|---|
Allergy Associates Medical Group is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Adherium (ASX.ADR) is a global leader in digital health technologies which address sub-optimal medication use in chronic disease.
JOINN Biologics is a Bay Area, California-based CMO company that is committed to the advancement of biopharmaceutics through its premier contract development and manufacturing services for biologics and advanced therapies. JOINN Biologics aims to provide a complete range of services from early custom development to clinical manufacturing for our global clients. We will work closely with our partners and clients to further accelerate the development of high-quality biologics to meet patient`s needs and deliver long-lasting value to biopharmaceutical industry.
Roche is a multinational healthcare company that creates innovative medicines and diagnostic tests to prevent, diagnose, and treat diseases. The company is committed to improving lives and making a sustainable contribution to society.
At Cerebral, we`re on a mission to democratize access to high-quality mental health care. We believe that everyone everywhere deserves to get the care they need, and are striving to make care convenient and accessible, while tackling the stigmas that surround mental illness. Since launching in January 2020, we have gone from a team of 5 to over 4,000 across the United States. With support from investors like SoftBank, Silver Lake, Access Industries, Bill Ackman, WestCap, and others, and impactful leaders like you, we`ll continue to democratize mental health care and double down on clinical quality and deliver exceptional patient outcomes for years to come. With a heavy focus on clinical quality and safety in all that we do, we`ve accomplished excellent patient outcomes: • 82% of patients report an improvement in their anxiety symptoms after using Cerebral. • 75% of patients who report improvement in their depression see improvement within 60 days. • 50% of patients who initially report suicidal ideation no longer harbor suicidal thoughts after treatment with Cerebral. This is just the beginning for Cerebral, and we won`t stop building, growing, and iterating until everyone, everywhere can access high-quality evidence-based mental health care without high costs and/or long wait times. We`re looking for mission-driven leaders who share these values, and we need your help as we transform access to high-quality mental health care in the United States and beyond.